Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca buys rights to Rigel's RA drug

AstraZeneca has signed a deal to buy the rights to Rigel's rheumatoid arthritis drug, fostamatinib disodium (R788)

AstraZeneca (AZ) has signed a deal to buy the rights to US-based Rigel's rheumatoid arthritis (RA) drug, fostamatinib disodium (R788), despite the treatment failing a phase IIb trial in July, 2009.

The drug had previously shown positive results in separate studies however, and AZ are keen to take advantage of what would be an oral alternative to injections for RA sufferers. The current treatment market for the autoimmune inflammatory disease is estimated to be around $13bn.

The deal will see AZ make an upfront payment of $100m, with up to an additional $345m payable if certain specified milestones in development, regulation and first commercial sales are achieved.

Rigel could also receive an additional $800m of specified sales-related milestone payments if the product achieves considerable commercial success and significant royalties on net sales worldwide.

Fostamatinib disodium is the furthest developed oral Spleen Tyrosine Kinase (Syk) inhibitor being evaluated for RA. This new treatment potentially offers an alternative for patients who have failed to respond adequately to a traditional disease modifying anti-rheumatic drug (DMARD), such as methotrexate, where a TNF biologic add-on treatment would currently be considered.

The drugs are proposed to work by blocking the intracellular signalling of various immune cells implicated in the destruction of bone and cartilage which is characteristic of RA.

AZ will assume responsibility for all development, regulatory filings, manufacturing and global commercialisation activities in all licensed indications.

A phase III programme is anticipated to begin in the second half of 2010, with the goal of filing new drug applications with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2013.

16th February 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics